Notably, the PI3K/AKT/mTOR pathway is a central regulator of hematopoietic cell proliferation, differentiation, and survival, and is activated in approximately 60% of AML patients, correlating with poor prognosis (Nepstad et al., 2020). This evidence concerns the gene MTOR and acute myeloid leukemia.